Stay updated on BMS-986466 Combo in KRAS G12C Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the BMS-986466 Combo in KRAS G12C Solid Tumors Clinical Trial page.

Latest updates to the BMS-986466 Combo in KRAS G12C Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedA U.S. NIH grant/contract reference was removed, and the website revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe clinical trial record for a study of BMS-986466 with adagrasib, with or without cetuximab, is available with its study details and results information. It indicates the study is terminated and no longer recruiting participants.SummaryDifference73%

- Check22 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH banner announces updates about the terminology transition from “Artificial Intelligence” to “Super Intelligence” across NIH content.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2, while the study record page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to BMS-986466 Combo in KRAS G12C Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BMS-986466 Combo in KRAS G12C Solid Tumors Clinical Trial page.